HSBC Holdings
NTLA icon

HSBC Holdings’s Intellia Therapeutics NTLA Stock Holding History

HSBC Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$614K Sell
48,259
-2,687
-5% -$34.2K ﹤0.01% 2125
2025
Q4 		$464K Sell
50,946
-3,617
-7% -$49.8K ﹤0.01% 2354
2025
Q3 		$904K Buy
54,563
+2,572
+5% +$31.7K ﹤0.01% 1839
2025
Q2 		$494K Buy
51,991
+3,057
+6% +$25.1K ﹤0.01% 2163
2025
Q1 		$343K Sell
48,934
-2,602
-5% -$26.3K ﹤0.01% 2296
2024
Q4 		$601K Buy
51,536
+16,569
+47% +$259K ﹤0.01% 2070
2024
Q3 		$722K Sell
34,967
-1,664
-5% -$38.4K ﹤0.01% 1836
2024
Q2 		$813K Buy
36,631
+2,067
+6% +$49.2K ﹤0.01% 1756
2024
Q1 		$951K Buy
34,564
+14,284
+70% +$397K ﹤0.01% 1798
2023
Q4 		$624K Buy
20,280
+152
+0.8% +$4.37K ﹤0.01% 1960
2023
Q3 		$635K Buy
+20,128
New +$781K ﹤0.01% 1893
2023
Q2 		– Sell
-21,571
Closed -$797K – 2686
2023
Q1 		$797K Buy
21,571
+13,075
+154% +$513K ﹤0.01% 1871
2022
Q4 		$292K Buy
+8,496
New +$404K ﹤0.01% 2572
2020
Q4 		– Sell
-23,091
Closed -$477K – 3107
2020
Q3 		$477K Buy
23,091
+3,022
+15% +$63K ﹤0.01% 1977
2020
Q2 		$422K Sell
20,069
-1,769
-8% -$30.1K ﹤0.01% 1938
2020
Q1 		$261K Buy
+21,838
New +$294K ﹤0.01% 2133

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HSBC Holdings's NTLA Position: Q1 2026 in Review

HSBC Holdings reduced its Intellia Therapeutics (NTLA) stake by 5.3% in Q1 2026, selling an estimated $34.2K and leaving 48,259 shares worth $614K. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

HSBC Holdings first reported a position in NTLA in Q1 2020 and has held it in 16 quarters since. The position peaked at $951K in Q1 2024. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • HSBC Holdings held 48,259 shares of Intellia Therapeutics worth $614K as of Q1 2026.
  • HSBC Holdings sold 2,687 Intellia Therapeutics shares in Q1 2026, an estimated $34.2K.
  • Intellia Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2125 holding.
  • HSBC Holdings first reported a position in Intellia Therapeutics in Q1 2020 and has held it in 16 quarters since.
  • HSBC Holdings's Intellia Therapeutics position peaked at $951K in Q1 2024.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.